Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus (DEFINE)

A Comparative Study of Entecavir vs. Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-resistant Chronic Hepatitis B Subjects: The DEFINE Study

The purpose of this study is to evaluate the effectiveness of entecavir plus adefovir combination therapy versus entecavir monotherapy or therapy with adefovir plus lamivudine

Study Overview

• Status: Completed
• Conditions: Hepatitis B, Chronic
• Intervention / Treatment: Drug: Entecavir; Drug: Tenofovir; Drug: Adefovir; Drug: Lamivudine

• Study Type: Interventional
• Enrollment (Actual): 629
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Concord, New South Wales, Australia, 2139
      • Local Institution
    • Randwick, New South Wales, Australia, 2031
      • Local Institution
• Brazil
  • Rio Grande Do Sul
    • Porto Alegre Rs, Rio Grande Do Sul, Brazil, 90035
      • Local Institution
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N 4N1
      • Local Institution
• Greece
  • Athens, Greece, 11527
    • Local Institution
• Hong Kong
  • Hong Kong, Hong Kong
    • Local Institution
  • Tai Po, Hong Kong
    • Local Institution
  • New Territories
    • Shatin, New Territories, Hong Kong
      • Local Institution
• India
  • Ahmedabad, India, 380006
    • Local Institution
  • Chandigarh, India, 160012
    • Local Institution
  • Indore, India, 452014
    • Local Institution
  • Ludhiana, India, 141001
    • Local Institution
  • New Delhi, India, 110002
    • Local Institution
  • Vellore, India, 632004
    • Local Institution
  • Uttar Pradesh
    • Lucknow, Uttar Pradesh, India, 226014
      • Local Institution
• Indonesia
  • Jakarta, Indonesia, 10350
    • Local Institution
• Italy
  • Antella, Firenze, Italy, 50012
    • Local Institution
• Korea, Republic of
  • Chuncheon-Si, Korea, Republic of, 200-704
    • Local Institution
  • Daegu, Korea, Republic of, 700-721
    • Local Institution
  • Gangneung, Korea, Republic of, 210-711
    • Local Institution
  • Incheon, Korea, Republic of, 405-760
    • Local Institution
  • Pusan, Korea, Republic of, 602-739
    • Local Institution
  • Seoul, Korea, Republic of, 110-744
    • Local Institution
  • Seoul, Korea, Republic of, 120-752
    • Local Institution
  • Seoul, Korea, Republic of, 135-710
    • Local Institution
  • Seoul, Korea, Republic of, 137-040
    • Local Institution
  • Seoul, Korea, Republic of, 138-736
    • Local Institution
  • Seoul, Korea, Republic of, 135-720
    • Local Institution
  • Seoul, Korea, Republic of, 136-705
    • Local Institution
  • Seoul, Korea, Republic of, 156-755
    • Local Institution
  • Seoul, Korea, Republic of, 152-703
    • Local Institution
  • Seoul, Korea, Republic of, 143-729
    • Local Institution
  • Suwon, Korea, Republic of, 443-721
    • Local Institution
  • Yangsan-Si, Korea, Republic of, 626770
    • Local Institution
  • Dongdaemun-Gu
    • Seoul, Dongdaemun-Gu, Korea, Republic of, 130-702
      • Local Institution
  • Donggu
    • Ulsan, Donggu, Korea, Republic of, 682-714
      • Local Institution
  • Gyeonggi-Do
    • Ansan-Si, Gyeonggi-Do, Korea, Republic of, 425-707
      • Local Institution
    • Anyang-Si, Gyeonggi-Do, Korea, Republic of, 431-070
      • Local Institution
    • Bucheon-Si, Gyeonggi-Do, Korea, Republic of, 420767
      • Local Institution
    • Seongnam-Si, Gyeonggi-Do, Korea, Republic of, 463 712
      • Local Institution
    • Suwon-Si, Gyeonggi-Do, Korea, Republic of, 442-723
      • Local Institution
  • Ilsanseo Gu
    • Koyang, Ilsanseo Gu, Korea, Republic of, 411-706
      • Local Institution
  • Jung-Gu
    • Incheon, Jung-Gu, Korea, Republic of, 400-711
      • Local Institution
  • Nowon-Gu
    • Seoul, Nowon-Gu, Korea, Republic of, 139-872
      • Local Institution
• Malaysia
  • Kuala Lumpur, Malaysia, 50603
    • Local Institution
  • Sabah
    • Kota Kinabalu, Sabah, Malaysia, 88586
      • Local Institution
• Philippines
  • Cebu City, Philippines, 6000
    • Local Institution
  • Manila, Philippines, 1502
    • Local Institution
• Poland
  • Chorzow, Poland, 41-500
    • Local Institution
  • Kielce, Poland, 25-317
    • Local Institution
  • Lodzi, Poland, 91-347
    • Local Institution
  • Lublin, Poland, 20-081
    • Local Institution
  • Warszawa, Poland, 01-201
    • Local Institution
• Russian Federation
  • Moscow, Russian Federation, 105275
    • Local Institution
  • Moscow, Russian Federation, 115446
    • Local Institution
  • St. Petersburg, Russian Federation, 190103
    • Local Institution
  • St. Petersburg, Russian Federation, 191167
    • Local Institution
• Singapore
  • Singapore, Singapore, 119074
    • Local Institution
• Taiwan
  • Kaohsiung, Taiwan, 80756
    • Local Institution
  • Tainan R.O.C., Taiwan, 70403
    • Local Institution
  • Taipei, Taiwan, 100
    • Local Institution
  • Taoyuan, Taiwan, 333
    • Local Institution
• Thailand
  • Bangkok, Thailand, 10700
    • Local Institution
  • Chiang Mai, Thailand, 50200
    • Local Institution
• Turkey
  • Bornova Izmir, Turkey, 35100
    • Local Institution
  • Trabzon, Turkey, 610808
    • Local Institution
• United States
  • Connecticut
    • Farmington, Connecticut, United States, 06030
      • University of Connecticut Health Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Evidence of lamivudine (LVD) resistance
• Subjects must have a history of previous LVD treatment at screening, and must have evidence of at least 1 LVD resistance substitution (valine, isoleucine, or serine) at reverse transcriptase codon 204 (M204V/I/S)
• Nucleoside- and nucleotide-naive, except for LVD, and had chronic hepatitis B (HBV) infection
• Compensated liver function and must have met ALL of the following criteria:International normalization ratio (INR) ≤ 1.5; Serum albumin ≥ 3 g/dL (≥ 30 g/L); Serum total bilirubin ≤ 2.5 mg/dL (≤ 42.75 μmol/L)
• HBV DNA > 1.72 x 10*4* IU/mL (approximately 10*5* copies/mL)
• Documentation of hepatitis B e antigen (HBeAg) positive and hepatitis B e antibody (HBeAb) negative status at screening
• alanine aminotransferase (ALT) ≤ 10 * upper limit of normal (ULN) at screening
• Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study (and for up to 6 weeks after the last dose of investigational product) in such a manner that the risk of pregnancy is minimized
• WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal. Post menopausal is defined as:
• Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential
• WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 72 hours prior to the start of investigational product

Exclusion Criteria:

• Evidence of decompensated cirrhosis
• Coinfection with human immunodeficiency virus, hepatitis C virus , or hepatitis D virus
• Women who are pregnant or breastfeeding
• Sexually active fertile men not using effective birth control if their partners were WOCBP
• Laboratory values out of protocol-specified range

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Entecavir; With the option of adding tenofovir at week 48. (This does not apply to Korea)	Drug: Entecavir; Tablets, Oral, 1mg, once daily, 100 weeks; Other Names: Baraclude; BMS-200475; Drug: Tenofovir; Tablets, Oral, 300 mg, once daily; Other Names: Viread
ACTIVE_COMPARATOR: Adefovir + Lamivudine	Drug: Adefovir; Tablets, Oral, 10mg, once daily, 100 weeks; Other Names: Hepsera; Drug: Lamivudine; Tablets, Oral, 100mg, once daily, 100 weeks; Other Names: Epivir
ACTIVE_COMPARATOR: Entecavir + Adefovir	Drug: Entecavir; Tablets, Oral, 1mg, once daily, 100 weeks; Other Names: Baraclude; BMS-200475; Drug: Adefovir; Tablets, Oral, 10mg, once daily, 100 weeks; Other Names: Hepsera

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48	HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay. HBV DNA less than (<)50 International units per milliliter (IU/mL) = approximately 300 copies/mL. Percentage of participants calculated n/N; n= number of participants with HBV DNA <50 IU/mL; N = number of participants analyzed.	Week 48

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 96	HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. HBV DNA < 50 IU/mL = approximately 300 copies/mL. Percentage n/N: n= number of participants with HBV DNA <50 IU/mL; N = number of participants analyzed.	Week 96
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48	HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed.	Week 48
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 96	HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed.	Week 96
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 48	HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.	Week 48
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 96	HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest amount or concentration of analyte in a sample, which can be reliably detected, but not necessarily quantified.	Week 96
Percentage of Participants With HBV DNA by PCR Category at Week 48	HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay.	Week 48
Percentage of Participants With HBV DNA by PCR Category at Week 96	HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay.	Week 96
Change in Mean log10 From Baseline in HBV DNA at Week 48	HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load, negative values means reduction.	Baseline, Week 48
Change in Mean log10 From Baseline in HBV DNA at Week 96	HBV DNA was analyzed by PCR, using the Roche COBAS® TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load.	Baseline, Week 96
Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 48	ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 or 48 U/L.	Week 48
Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 96	ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L.	Baseline, Week 96
Percentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only)	HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week	Week 48
Percentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only)	HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week	Week 96
Percentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only)	HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).	Week 48
Percentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only)	HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).	Week 96
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48	HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.	Week 48
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96	HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.	Week 96
Percentage of Participants With HBsAg Seroconversion at Week 48	HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.	Week 48
Percentage of Participants With HBsAg Seroconversion at Week 96	HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.	Week 96
Cumulative Probability of Emergent Genotypic Resistance at Year 1	yr=year. Cumulative probability (CP): Ptotal=1-(1-Pyr1)*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An "event" is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only).	Year 1
Cumulative Probability of Emergent Genotypic Resistance at Year 2	Cumulative probability (CP): Ptotal=1-(1-Pyr1)*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An "event" is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only).	Year 2
Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to Adverse Events or Laboratory Abnormalities During Treatment	AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Grade 1 = mild, Grade 2= moderate, Grade 3 = severe, Grade 4 = life threatening/disabling, Grade 5 = death.	From start of study therapy through Week 100 + 5 days
Number of Participants With Laboratory Abnormalities: Hematology	Criteria for hematology abnormalities were: Hemoglobin: <=11.0 g/dL; White Blood Cells: <4000/mm^3; Absolute Neutrophils (includes absolute bands): <1500/mm^3; Platelets: <=99,000/mm^3; International Normalized Ratio: ≥ 1.5 and ≥ 0.5 from baseline.	From start of study through Week 100 + 5 days
Number of Participants With Laboratory Abnormalities: Serum Chemistry	ULN=upper limit of normal (Normal ranges are Central lab data and vary according to the site). ALT:>1.25*ULN, AST:>1.25*ULN, ALP:>1.25*ULN, Total Bilirubin:>1.1*ULN, Serum Lipase:>1.10*ULN, Creatinine:>1.1*ULN, Blood Urea Nitrogen:1.25*ULN, Hyperglycemia:>116 mg/dL, Hypoglycemia:<64 mg/dL, Hyponatremia:<132meq/L, Hypokalemia:<3.4 meq/L, Albumin:≥1g/dL decrease from baseline, <3 g/dL; Hypernatremia:>148 meq/L, Hyperkalemia:>5.6 meq/L, Hypokalemia:<3.4 meq/L, Hyperchloremia:>113 meq/L, Hypochloremia:<93 meq/L; ALT flare: on treatment (OT), >2*Baseline and >10*ULN; off treatment (OF), 2*end of dosing value and >10*ULN	On treatment : Day 1 through Week 100 + 5 days; Offtreatment = End of OT period through 24 weeks

Collaborators and Investigators

• Sponsor: Bristol-Myers Squibb

Study record dates

Study Major Dates

• Study Start: March 1, 2008
• Primary Completion (ACTUAL): January 1, 2011
• Study Completion (ACTUAL): July 1, 2012

Study Registration Dates

• First Submitted: December 11, 2006
• First Submitted That Met QC Criteria: December 11, 2006
• First Posted (ESTIMATE): December 12, 2006

Study Record Updates

• Last Update Posted (ESTIMATE): November 21, 2013
• Last Update Submitted That Met QC Criteria: October 29, 2013
• Last Verified: October 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Enterovirus Infections; Picornaviridae Infections; Hepatitis, Chronic; Hepatitis B; Hepatitis; Hepatitis A; Hepatitis B, Chronic; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Tenofovir; Entecavir; Lamivudine; Adefovir
• Other Study ID Numbers: AI463-111